Transgene S.a.

Btg International Limited

Pharmaceutical Proteins Limited

The University of Edinburgh

Aventis Behring Gmbh

Ppl Therapeutics (scotland) Limited

Richard Lathe

Marie-Paule Kieny

Pierre H Chambon

Anthony John Clark

Mara Hareuveni

Kenneth Andrew Rose

Jean-Pierre Lecocq

Robert Drillien

Guerrino Meneguzzi

Genevieve Stapleton

Gerhard Dickneite

Hubert Metzner

Eric Degryse

Jonathan Robert Seckl

Gilles Cauet

Gerd Zettlmeissl

Ulrich Grundmann

Meng Li

Ruth Best

Austin Smith

Pedro Vico

Caroline McKenzie Leckie

Joyce Lai Wah Yau

The invention concerns a novel method for producing hydroxylated and/or acetylated steroid comprising steps which consist in: culturing yeasts on a medium comprising at least a precursor of such hydroxylated and/or acetylated steroids; then isolating the hydroxylated and/or acetylated steroids from the medium after bioconversion. Said method is characterized in that said yeasts are yeasts transformed so as to express the product of Cypb gene. The invention also concerns the modified yeast strains.

Method for preparing steroids modified by yeast fermentation

Use is provided for a 7&agr;-hydroxy or 7-oxo substituted 3&bgr;-hydroxy-steroid possessing the carbon skeleton of cholesterol, androsterone, pregnenolone or estradiol, or an analogue thereof substituted independently at one or both of the 7- and 3-positions with an ester or ether group, in the manufacture of a pharmaceutical composition for the therapy of neuropsychiatric, immune and/or endocrine disorders or for inducing cognitive enhancement. Uses for Cyp7b enzymes in producing such steroids is also provided together with various novel steroids and test kits and methods for diagnosing the disorders.

Use of 7 &agr;-substituted steroid to treat neuropsychiatric, immune or endocrine disorders

Pharmaceutical compositions are disclosed which comprise recombinant viruses containing a DNA fragment encoding a polypeptide recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptide specifically bound by antibody H23.

Pharmaceutical composition for the treatment or prevention of a malignant tumor

The invention provides a transgenic mouse which is heterozygous or homozygous for an at least partially defective coagulation factor XIII gene.

Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding

The application provides a polypeptide and a pharmaceutical composition which comprises said polypeptide, wherein said polypeptide is recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells. This antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the polypeptides specifically bound by antibody H23.

This invention provides novel hippocampus-associated proteins and DNA sequences coding therefor. In an investigation of hippocampus-associated proteins by differential screening of a rat hippocampus cDNA library, a cDNA species encoding a novel protein designated Hct-1 was isolated and shown to be a to cytochromes P450. The use of hybridization probes based on the rat Hct-1 sequence has led to the identification of homologues in other mammalian species.

Hippocampus-associated proteins, DNA sequences coding therefor and uses thereof

The present invention relates to a vaccinia virus, characterised in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.

Vaccine against rabies and process for preparation thereof

The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of the DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.

Expression of a tumor-specific antigen by a recombinant vector virus and

Hippocampus-associated proteins; DNA sequences coding therefor and uses

A pharmaceutical composition which comprises a recombinant vaccinia virus containing a DNA fragment encoding for a polypeptide recognized by a particular antibody H23, which recognizes a particular tumor antigen expressed on breast cancer cells is provided. The antibody specifically binds to an epitope comprising a tandem repeat sequence of 20 amino acids comprised in a transmembrane form as well as a secreted form of the POLYPEPTIDES specifically bound by antibody H23.

Pharmaceutical composition for the treatment of a malignant tumor

The present invention relates to a vaccinia virus, characterized in that it contains all or part of a DNA sequence (I) coding for an antigenic glycoprotein of rabies.

The invention concerns a vector being vaccinia virus, which comprises a heterologous DNA sequence which codes at least for the essential region of a tumor specific protein called T antigen, cloned within a non essential region of the vaccinia virus, as well as regulatory element required for the expression of said DNA sequence in higher cells, the vector is particularly useful as a pharmaceutical composition having a preventive or creative activity against tumors especially tumors caused by a papillomavirus.

A method of producing a proteinaceous compound, involves incorporating a DNA sequence coding for polypeptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The proteinaceous compound may be a (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The proteinaceous compound will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.

Peptide production

A method of producing a substance comprising a peptide, involves incorporating a DNA sequence coding for the peptide into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The substance may be an (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The substance will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.

A method of producing a proteinaceous compound, involves incorporating a DNA sequence coding for a polypeptide chain of said compound into a gene of a mammal (such as a sheep) coding for a milk whey protein in such a way that the DNA sequence is expressed in the mammary gland of the adult female mammal. The proteinaceous compound may be a (optionally modified) protein such as a blood coagulation factor. The DNA sequence is preferably inserted into the first exon of a gene coding for a whey protein such as beta-lactoglobulin. The proteinaceous compound will generally be recovered from milk of the female mammal, but may (for example if it is an enzyme) be used in situ.

Growing community of inventors

Strasbourg, France

Richard Lathe